Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity.

@article{Cho2007SirolimusTO,
  title={Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity.},
  author={Monique E Cho and John Kevin. Hurley and Jeffrey B Kopp},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2007},
  volume={49 2},
  pages={
          310-7
        }
}
To evaluate the safety and efficacy of sirolimus in treating patients with focal segmental glomerulosclerosis (FSGS), we performed a phase 2, open-label clinical trial. Inclusion criteria were adults and children 13 years and older with biopsy-proven idiopathic FSGS, proteinuria with protein of 3.5 g/d or greater while on angiotensin antagonist therapy, glomerular filtration rate (GFR) of 30 mL/min/1.73 m(2) or greater (>or=0.50 mL/s), and failure to achieve sustained remission with at least 1… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Focal Segmental Glomerulosclerosis.

  • Clinical journal of the American Society of Nephrology : CJASN
  • 2017
VIEW 3 EXCERPTS
CITES BACKGROUND

Podocyte Growing Pains in Adaptive FSGS.

  • Journal of the American Society of Nephrology : JASN
  • 2017

Targeting mTOR Signaling Can Prevent the Progression of FSGS.

  • Journal of the American Society of Nephrology : JASN
  • 2017